Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants
Public ClinicalTrials.gov record NCT03041116. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Patients: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension
Study identification
- NCT ID
- NCT03041116
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Enrollment
- 84 participants
Conditions and interventions
Interventions
- Fosmetpantotenate Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 16, 2017
- Primary completion
- Dec 29, 2019
- Completion
- Dec 29, 2019
- Last update posted
- Jan 25, 2021
2017 – 2019
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Travere Investigational Site | Irvine | California | 92697 | — |
| Travere Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| Travere Investigational Site | Miami | Florida | 33155 | — |
| Travere Investigational Site | Decatur | Georgia | 30033 | — |
| Travere Investigational Site | Chicago | Illinois | 60612 | — |
| Travere Investigational Site | Boston | Massachusetts | 02114 | — |
| Travere Investigational Site | New York | New York | 10032 | — |
| Travere Investigational Site | Pittsburgh | Pennsylvania | 15224 | — |
| Travere Investigational Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03041116, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 25, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03041116 live on ClinicalTrials.gov.